| Ytd | -15.98% | |
| 1y | 72.75% |
| Open | 13.36 | Prev Close | 13.42 | Low | 13.25 | High | 13.82 | Mkt Cap | 311.57M |
| Vol | 8.13K | Avg Vol | 214.94K | EPS | -2.59 | P/E | -5.18 | Forward P/E | -1.32 |
| Beta | 0.96 | Short Ratio | 20.91 | Inst. Own | 100.66% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-10 | 50-d Avg | 13.32 | 200-d Avg | 13.24 | 1yr Est | 16.88 |
ENTA News
Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. Th
HC Wainwright & Co. analyst Brandon Folkes reiterates Enanta Pharma (NASDAQ:ENTA) with a Buy
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biot
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biot
US stock futures lower, Braze Inc (BRZE) shares drop 8.4% in pre-market trading after reporting mixe
[url="]Enanta Pharmaceuticals, Inc.[/url] (NASDAQ: ENTA), a clinical-stage biotechnology company ded
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biot
Phreesia (NYSE: PHR) shares rose in pre-market trading after better-than-expected sales results. Oth
Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $0.45 per share versus the Zacks Con
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biot
Enanta Pharmaceuticals (ENTA) witnessed a jump in share price last session on above-average trading
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biot
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biot
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biot
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA - Get Free Report) passed below its 200-day moving averag
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biot
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biot
Enanta Pharmaceuticals (ENTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimis
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biot
Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $0.42 per share versus the Zacks Con
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biot
KalVista Pharmaceuticals (NASDAQ: KALV - Get Free Report) and Enanta Pharmaceuticals (NASDAQ: ENTA -
Shares of Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA - Get Free Report) have been given a consensus
Companies Reporting Before The Bell • Madison Square Garden (NYSE:MSGE) is expected to report quart
On Thursday, 369 companies hit new 52-week lows.
On Tuesday, 647 companies set new 52-week lows.
During Thursday's session, 406 companies made new 52-week lows.
During Wednesday's session, 212 companies made new 52-week lows.
Stocks That Hit 52-Week Lows On Friday
Stocks That Hit 52-Week Lows On Thursday
Stocks That Hit 52-Week Lows On Tuesday